<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03443414</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-CO-203</org_study_id>
    <nct_id>NCT03443414</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>Phase IIb, Randomized, Double Blind, Placebo Controlled, Dose Ranging Study to Assess the Effect of RPL554 in Patients With Moderate to Severe COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the effect of 4 weeks of twice daily treatment of four different doses
      of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo in patients with moderate to
      severe COPD. Patients will be equally allocated to one of the five treatment options.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RPL554 is a dual inhibitor of PDE3 and PDE4 which are known to have a role in modulating the
      inflammatory airway response in respiratory diseases, including COPD. PDE3 inhibitors act as
      bronchodilators whilst PDE4 inhibitors have anti-inflammatory properties and there is also
      evidence to suggest that combined inhibition of PDE3 and PDE4 can have additive or
      synergistic anti-inflammatory and bronchodilator. PDE4 inhibitors (administered orally) have,
      however been associated with unfavorable gastrointestinal side effects such as nausea,
      emesis, diarrhea, abdominal pain, loss of appetite and weight loss. Dual PDE3/PDE4 inhibitors
      (administered by inhalation) have exhibited both bronchodilator and ant-inflammatory actions,
      with a more favorable side effect profile. It is plausible that increased efficacy with
      reduced side effects may be achievable with administration of a dual PDE3/4 inhibitor by the
      inhaled route compared to orally administered PDE3 or PDE4 inhibitors.

      The purpose of this study is to investigate the dose response of RPL554 in patients with COPD
      over 4 weeks. This length of time should allow for study of the bronchodilator response,
      measured predominantly by the peak forced expired volume in one second (FEV1), and the
      anti-inflammatory response, as measured predominantly by trough FEV1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">February 7, 2018</completion_date>
  <primary_completion_date type="Actual">January 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The nebuliser cup will be obscured to prevent the Investigator or outcomes assessor so the contents are not visible to the Investigator our outcomes assessor. The visual appearance of the study medication will not be discussed with the subject</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peak FEV1 change from baseline at end of treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Maximum FEV1 in the 3 hours post-dose after 4 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 change from baseline at end of treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Morning pre-dose FEV1 after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average FEV1 change from baseline over 12 hours</measure>
    <time_frame>4 weeks</time_frame>
    <description>Area under the curve (AUC) over 12 hours at the start of treatment and after 4 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 change from baseline over 3 hours at the start and end of treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Maximum FEV1 over 3 hours at the start of treatment and after 4 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average FEV1 change from baseline over 3 hours at the start and end of treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>AUC FEV1 over 3 hours at the start of treatment and after 4 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in COPD symptoms</measure>
    <time_frame>Daily for 4 weeks</time_frame>
    <description>Change from baseline in COPD symptoms using The Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in breathlessness using the St George's Respiratory Questionnaire-COPD specific</measure>
    <time_frame>After 2 and 4 weeks of treatment</time_frame>
    <description>Change from baseline in breathlessness using the St George's Respiratory Questionnaire-COPD specific</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in breathlessness using Medical Research Council Questionnaire</measure>
    <time_frame>After 2 and 4 weeks of treatment</time_frame>
    <description>Change from baseline in breathlessness using the Medical Research Council Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of dyspnea</measure>
    <time_frame>After 2 and 4 weeks of treatment</time_frame>
    <description>Assessment of dyspnea using the Traditional Dyspnea Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient assessment of change in breathing</measure>
    <time_frame>After 2 and 4 weeks of treatment</time_frame>
    <description>Assessment of breathing compared to baseline using the Patient Global Assessment of Change Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change from baseline in albuterol/salbutamol use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Incidence of adverse events by system organ class and preferred term</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemistry</measure>
    <time_frame>After 2 and 4 weeks of treatment</time_frame>
    <description>Number of patients with out of range results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology</measure>
    <time_frame>After 2 and 4 weeks of treatment</time_frame>
    <description>Number of patients with out of range results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead electrocardiogram (ECG)</measure>
    <time_frame>Pre-dose and 2 hours after the first dose and after 1, 2, 3 and 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Up to 12 hours post dose after the first dose and after 1, 2, 3 and 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Holter monitoring</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">403</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>0.75 mg RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 mg RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6 mg RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPL554 suspension</intervention_name>
    <description>A dual PDE3/PDE 4 inhibitor</description>
    <arm_group_label>0.75 mg RPL554</arm_group_label>
    <arm_group_label>1.5 mg RPL554</arm_group_label>
    <arm_group_label>3 mg RPL554</arm_group_label>
    <arm_group_label>6 mg RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide informed consent

          -  Male or female aged 40 to 75 years

          -  Meeting specified contraception requirements

          -  12-lead ECG with heart rate 50-90 beats per minute, QT interval corrected using
             Fridericia's formula (QTcF) ≤450 msec (males) or ≤470 msec (females), QRS interval
             ≤120 msec, PR interval ≤200 msec and no clinically significant abnormalities

          -  Capable of complying with all study restrictions and procedures, including ability to
             use the study nebulizer correctly.

          -  Body mass index (BMI) 18 to 35 kg/m2 and minimum weight 45 kg.

          -  COPD diagnosis with symptoms compatible with COPD for at least 1 year

          -  Clinically stable COPD in the previous 4 weeks

          -  Ability to perform acceptable and reproducible spirometry.

          -  Post-bronchodilator spirometry at screening must demonstrate FEV1/forced vital
             capacity (FVC) ratio of ≤0.70 and FEV1 must be ≥40 % to ≤80% of predicted normal

          -  Chest X-ray (posterior-anterior) at screening, or chest X-ray, magnetic resonance
             imaging (MRI) or computed tomography (CT) scan in the last 12 months, showing no
             abnormalities which are both clinically significant and unrelated to COPD.

          -  Meet the concomitant medication restrictions and be expected to do so for the rest of
             the study.

          -  Current and former smokers with a smoking history of ≥10 pack years.

          -  Capable of withdrawing long acting bronchodilators until the end of the treatment
             period, and short acting bronchodilators for 8 hours prior to administration of study
             medication.

        Exclusion Criteria:

          -  A history of life-threatening COPD including Intensive Care Unit admission and
             requiring intubation.

          -  COPD exacerbation requiring oral steroids in the previous 3 months

          -  A history of one or more hospitalizations for COPD in the previous 6 months

          -  Lower respiratory tract infection treated with antibiotics in the previous 3 months

          -  Evidence of cor pulmonale or clinically significant pulmonary hypertension.

          -  Patients with a current diagnosis of asthma, active tuberculosis, lung cancer,
             bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnea,
             known alpha-1 antitrypsin deficiency or other active pulmonary diseases.

          -  Previous lung resection or lung reduction surgery.

          -  Oral therapies for COPD (e.g. oral steroids, theophylline, and roflumilast) in the
             previous 3 months and throughout the study.

          -  Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to
             Visit 1) and remains stable during the trial.

          -  A history of, or reason to believe a subject has, drug or alcohol abuse in the
             previous 3 years.

          -  Received an experimental drug within 30 days or five half-lives of the first dose

          -  Prior exposure to RPL554.

          -  Women who are pregnant or breast-feeding.

          -  Patients with a history of current uncontrolled disease that the Investigator believes
             are clinically significant.

          -  myocardial infarction in the previous 6 month; congestive heart failure, a history of
             unstable or uncontrolled hypertension, or has been diagnosed with hypertension in last
             3 months.

          -  Use of oral beta blockers.

          -  Major surgery (requiring general anesthesia) in the previous 6 weeks, lack of full
             recovery from surgery at screening, or planned surgery through the end of the study.

          -  History of malignancy of any organ system within 5 years, with the exception of
             localized skin cancers (basal or squamous cell).

          -  Clinically significant abnormal values for safety laboratory tests

          -  Significant non-compliance in previous investigational studies or with prescribed
             medications.

          -  Requirement for oxygen therapy, even on an occasional basis.

          -  Known hypersensitivity to RPL554 or its excipients/components.

          -  Abnormal clinically significant 12 lead Holter findings,

          -  Any other reason that the Investigator considers makes the subject unsuitable to
             participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinic for pneumonology</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATPPD-Ruse EOOD</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fifth MHAT - Sofia EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT 'Lyulin', EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NMTH Tsar Boris III</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT 'Alexandrovska' EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT 'Sveta Anna' AD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Nov</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediTrial s.r.o.</name>
      <address>
        <city>Jindřichův Hradec</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plicni stredisko Teplice</name>
      <address>
        <city>Teplice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aerzte fuer Lungen- und</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienpraxis Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKF Pneumologie GmbH &amp; Co. KG</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Keller</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inamed GmbH</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRI Pulmonary Research</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburger Institut fuer</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>POIS Leipzig GbR</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SALVUS UG Centre for Clinial Trials</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLB Gesundheitsforschung</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologie Odeonsplatz</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologische Praxis Pasing</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ballenberger Freytag Wenisch</name>
      <address>
        <city>Neu Isenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Christian Schlenska</name>
      <address>
        <city>Peine</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CERMED</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLIMED Marek Klimkiewicz</name>
      <address>
        <city>Bychawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silmedic sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grazyna Pulka Specjalistyczny</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Alergologii</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Alergo-MEDSpecjalistyczna</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Network Sp z o o</name>
      <address>
        <city>Skierniewice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowieckie Centrum Medyczne</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Opieka</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Terapii Wspólczesnej</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Klin</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C Angisan S.R.L</name>
      <address>
        <city>Bragadiru</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C Clinica Pneumomedica S.R.L</name>
      <address>
        <city>Braşov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundatia Dr. Victor Babes</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Cl. Pneumoftiziologie</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul CldePneumoftiziologie</name>
      <address>
        <city>Constanţa</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul CldePneumoftiziologie</name>
      <address>
        <city>Iaşi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>May 6, 2018</last_update_submitted>
  <last_update_submitted_qc>May 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD, bronchodilation, FEV1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

